{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The number and percentage of patients who were in Hospice Care prior to death. Analyzed for the 10 patients who died as of last follow-up Dec. 1st 2023.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023; and who died prior to December 1, 2023.","id":"OG000","title":"Multiple Myeloma/Blenrep Participants Who Died"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Hospice Care Given Prior to Death","type":"POST_HOC","unitOfMeasure":"Participants"}